Mesothelin Targeting T Cell Therapy - Eureka Therapeutics
Latest Information Update: 30 Mar 2023
At a glance
- Originator Eureka Therapeutics
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Mar 2023 Mesothelin Targeting antibody licensed to Eureka therapeutics
- 14 Mar 2023 Preclinical trials in Solid tumours in USA (Parenteral)
- 14 Mar 2023 Eureka Therapeutics plans to submit IND application with US FDA